This Article Full Text Full Text (PDF) All Versions of this Article: 117/8/1075    most recent CIRCULATIONAHA.107.722868v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jörgensen, K. Articles by Ricksten, S.-E. Search for Related Content PubMed PubMed Citation Articles by Jörgensen, K. Articles by Ricksten, S.-E. Related Collections Other heart failure Cardiovascular Pharmacology Hypertrophy CV surgery: valvular disease Related Article

(Circulation. 2008;117:1075-1081.)
© 2008 American Heart Association, Inc.

Valvular Heart Disease

Effects of Levosimendan on Left Ventricular Relaxation and Early Filling at Maintained Preload and Afterload Conditions After Aortic Valve Replacement for Aortic Stenosis

Kirsten Jörgensen, MD; Odd Bech-Hanssen, MD, PhD; Erik Houltz, MD, PhD; Sven-Erik Ricksten, MD, PhD

From the Department of Cardiothoracic Anesthesia and Intensive Care (K.J., E.H., S.-E.R.) and Department of Clinical Physiology (O.B.-H.), Sahlgrenska University Hospital, Gothenburg, Sweden, and Department of Anaesthesia, Pain and Hyperbaric Medicine, Royal Adelaide Hospital, Adelaide, Australia (K.J.).

Correspondence to Sven-Erik Ricksten, MD, PhD, Department of Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden. E-mail sven-erik.ricksten{at}aniv.gu.se

Received June 29, 2007; accepted December 14, 2007.

Background— We determined the effects of levosimendan, a calcium sensitizer, on left ventricular (LV) diastolic function in patients with LV hypertrophy.

Methods and Results— In this prospective, randomized, blinded study, 23 patients received either levosimendan (0.1 and 0.2 µg · kg^–1 · min^–1; n=12) or placebo (n=11) after aortic valve replacement for aortic stenosis. The effects on LV performance, dimensions, filling patterns, and isovolumic relaxation time, as well as systemic hemodynamics, were assessed by pulmonary artery thermodilution catheterization and transesophageal 2-dimensional Doppler echocardiography. To circumvent the confounding effects of the levosimendan-induced hemodynamic changes on Doppler echocardiographic indexes of LV early relaxation, heart rate and mean arterial and central venous pressures were kept constant during levosimendan/placebo infusion by atrial pacing, vasopressor, and colloid infusions. In the levosimendan group, dose-dependent increases in cardiac output (28%; P<0.001) and stroke volume (26%; P<0.001) and a decrease in systemic vascular resistance (–22%; P<0.001) were observed. There was a trend for an increase in LV ejection fraction (12%; P=0.058) with levosimendan. There were no significant differences in systolic, diastolic arterial, or LV filling pressures or LV end-diastolic area between the 2 groups. Isovolumic relaxation time decreased (–23%; P<0.001), as did the deceleration slope of early diastolic filling (–45%; P<0.01), whereas peak early diastolic filling velocity (16%, P<0.01) and peak late diastolic filling velocity (15%; P<0.001) increased after levosimendan compared with placebo.

Conclusion— Levosimendan, in addition to its inotropic effects, exerts a direct positive lusitropic effect in patients with LV hypertrophy as it shortens isovolumic relaxation time and improves LV filling.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 117: 987-989. [Extract] [Full Text]

This article has been cited by other articles:

				N. J. Palpant, L. G. D'Alecy, and J. M. Metzger Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo FASEB J, May 1, 2009; 23(5): 1529 - 1540. [Abstract] [Full Text] [PDF]

				M. T. Maeder and D. M. Kaye Heart failure with normal left ventricular ejection fraction. J. Am. Coll. Cardiol., March 17, 2009; 53(11): 905 - 918. [Abstract] [Full Text] [PDF]

				H. I. Eriksson, J. R. Jalonen, L. O. Heikkinen, M. Kivikko, M. Laine, K. A. Leino, A. H. Kuitunen, K. T. Kuttila, T. K. Perakyla, T. Sarapohja, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann. Thorac. Surg., February 1, 2009; 87(2): 448 - 454. [Abstract] [Full Text] [PDF]